TAKEDA PHARMACEUTICAL CO LTD (TAK) Form 6-K — Aug 5, 2026
The U.S. Food and Drug Administration has approved ORZEYFUL (oveporexton), an oral orexin receptor 2 agonist, for the treatment of narcolepsy type 1 in adults. This is the first and only medicine in the U.S. to treat the underlying cause of the disease, offering a holistic approach to symptom management.
Key figures
- Drug Name
- ORZEYFUL (oveporexton)
- Mechanism
- Orexin receptor 2 (OX2R) agonist
- Indication
- Narcolepsy Type 1 (NT1) in adults
- Launch Status
- Pending DEA scheduling (expected within 90 days)
- Approval Status
- FDA Approved
- Clinical Trials
- Phase 3 FirstLight (TAK-861-3001) and RadiantLight (TAK-861-3002)
- Contraindication
- Strong CYP3A inhibitors
- Target Population US
- 120,000 people
- Common Adverse Reactions
- ["Insomnia","Urinary frequency","Urinary urgency","Excessive saliva"]
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.